Sarah A. Carratt

An industry perspective on the FDA Modernization Act 2.0/3.0: potential next steps for sponsors to reduce animal use in drug development

Sarah A. Carratt, Christina L Zuch de Zafra, Elias M. Oziolor et al. · Toxicological Sciences · 2024 · 48 citations · Full text

Pharmacy, Pharmaceutical Policy, Drug Approval Processes +16

Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia

Theodore P. Braun, Mariam Okhovat, Cody Coblentz et al. · Nature Communications · 2019 · 36 citations · Full text

Medicine, Cancer Biology, Oncology +17

Human CYP2A13 and CYP2F1 Mediate Naphthalene Toxicity in the Lung and Nasal Mucosa of CYP2A13/2F1-Humanized Mice

Lei Li, Sarah A. Carratt, Matthew Hartog et al. · Environmental Health Perspectives · 2017 · 33 citations · Full text

Pharmacy, Pharmacology, Toxicology +17

Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia

Theodore P. Braun, Cody Coblentz, Brittany M. Curtiss et al. · Proceedings of the National Academy of Sciences · 2020 · 32 citations · Full text

Medicine, Oncology, Pharmacology +14

Metabolism and Lung Toxicity of Inhaled Naphthalene: Effects of Postnatal Age and Sex

Sarah A. Carratt, Nataliia Kovalchuk, Xinxin Ding et al. · Toxicological Sciences · 2019 · 31 citations · Full text

Pharmacy, Pathobiology, Toxicology +17